120 related articles for article (PubMed ID: 36738085)
1. The impact of COVID-19 on trends in alcohol use disorder treatment in Veterans Health Administration.
Perumalswami PV; Kilpatrick S; Frost MC; Adams MA; Kim HM; Zhang L; Lin L
Addiction; 2023 Jun; 118(6):1062-1071. PubMed ID: 36738085
[TBL] [Abstract][Full Text] [Related]
2. Telehealth and delivery of alcohol use disorder treatment in the Veterans Health Administration.
Perumalswami PV; Adams MA; Frost MC; Holleman R; Kim HM; Zhang L; Lin LA
Alcohol Clin Exp Res (Hoboken); 2024 May; 48(5):944-954. PubMed ID: 38529689
[TBL] [Abstract][Full Text] [Related]
3. Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder.
Lin LA; Zhang L; Kim HM; Frost MC
Am J Psychiatry; 2022 Oct; 179(10):740-747. PubMed ID: 35899380
[TBL] [Abstract][Full Text] [Related]
4. National Veterans Health Administration MOVE! Weight Management Program Participation During the COVID-19 Pandemic.
Gray KE; Hoerster KD; Spohr SA; Breland JY; Raffa SD
Prev Chronic Dis; 2022 Mar; 19():E11. PubMed ID: 35271436
[TBL] [Abstract][Full Text] [Related]
5. Rural Veterans with HIV and Alcohol Use Disorder receive less video telehealth than urban Veterans.
Sheinfil AZ; Day G; Walder A; Hogan J; Giordano TP; Lindsay J; Ecker A
J Rural Health; 2024 Jun; 40(3):419-429. PubMed ID: 37759376
[TBL] [Abstract][Full Text] [Related]
6. Receipt of pharmacotherapy for alcohol use disorder by justice-involved women in the Veterans Health Administration.
Taylor E; Timko C; Harris AHS; Yu M; Finlay AK
Addict Sci Clin Pract; 2019 Jan; 14(1):1. PubMed ID: 30602392
[TBL] [Abstract][Full Text] [Related]
7. Healthcare Utilization Differences Among Primary Care Patients Using Telemedicine in the Veterans Health Administration: a Retrospective Cohort Study.
O'Shea AMJ; Mulligan K; Carlson P; Haraldsson B; Augustine MR; Kaboli PJ; Shimada SL
J Gen Intern Med; 2024 Feb; 39(Suppl 1):109-117. PubMed ID: 38252240
[TBL] [Abstract][Full Text] [Related]
8. Telehealth-delivered Psychotherapy for the Treatment of Alcohol Use Disorder: Patient Perspectives in the Age of COVID-19.
Girard R; Foreman J; Pinnette E; Bonar EE; Fernandez A; Lin LA
J Addict Med; 2023 Nov-Dec 01; 17(6):e367-e373. PubMed ID: 37934529
[TBL] [Abstract][Full Text] [Related]
9. Changes in the Use of Telehealth and Face-To-Face Chiropractic Care in the Department of Veterans Affairs Before and After the COVID-19 Pandemic.
Roytman GR; Coleman BC; Corcoran KL; Goertz CM; Long CR; Lisi AJ
J Manipulative Physiol Ther; 2021 Sep; 44(7):584-590. PubMed ID: 35249749
[TBL] [Abstract][Full Text] [Related]
10. Alcohol-related and mental health care for patients with unhealthy alcohol use and posttraumatic stress disorder in a National Veterans Affairs cohort.
Chen JA; Owens MD; Browne KC; Williams EC
J Subst Abuse Treat; 2018 Feb; 85():1-9. PubMed ID: 29291765
[TBL] [Abstract][Full Text] [Related]
11. Prevalence, risk and protective factors of alcohol use disorder during the COVID-19 pandemic in U.S. military veterans.
Na PJ; Norman SB; Nichter B; Hill ML; Rosen MI; Petrakis IL; Pietrzak RH
Drug Alcohol Depend; 2021 Aug; 225():108818. PubMed ID: 34171825
[TBL] [Abstract][Full Text] [Related]
12. Impact of VA's video telehealth tablets on substance use disorder care during the COVID-19 pandemic.
Gujral K; Van Campen J; Jacobs J; Kimerling R; Zulman DM; Blonigen D
J Subst Use Addict Treat; 2023 Jul; 150():209067. PubMed ID: 37164153
[TBL] [Abstract][Full Text] [Related]
13. Effects of a multifaceted implementation intervention to increase utilization of pharmacological treatments for alcohol use disorders in the US Veterans Health Administration.
Harris AHS; Brown R; Dawes M; Dieperink E; Myrick DH; Gerould H; Wagner TH; Wisdom JP; Hagedorn HJ
J Subst Abuse Treat; 2017 Nov; 82():107-112. PubMed ID: 29021108
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Substance Use Disorder Diagnosis Rates From Electronic Health Record Data With Substance Use Disorder Prevalence Rates Reported in Surveys Across Sociodemographic Groups in the Veterans Health Administration.
Williams EC; Fletcher OV; Frost MC; Harris AHS; Washington DL; Hoggatt KJ
JAMA Netw Open; 2022 Jun; 5(6):e2219651. PubMed ID: 35771574
[TBL] [Abstract][Full Text] [Related]
15. Treatment utilization and modality preference among veterans receiving outpatient substance use disorder treatment during a pandemic.
Meshberg-Cohen S; Farook M; Gross G; Levina V; DeViva J
Am J Addict; 2023 Jan; 32(1):32-39. PubMed ID: 36286598
[TBL] [Abstract][Full Text] [Related]
16. Geographic differences in receipt of addictions treatment in a national sample of patients with alcohol use disorders from the U.S. Veterans Health Administration.
Edmonds AT; Bensley KM; Hawkins EJ; Williams EC
Subst Abus; 2021; 42(4):559-568. PubMed ID: 32821028
[No Abstract] [Full Text] [Related]
17. Impact of COVID-19 on stimulant use disorder treatment: A national cohort study in the Veterans Health Administration.
Coughlin LN; Frost MC; Zhang L; Lin LA
Drug Alcohol Depend; 2023 Nov; 252():110965. PubMed ID: 37769514
[TBL] [Abstract][Full Text] [Related]
18. Impact of the COVID-19 Pandemic on the Provision of Dialysis Service and Mortality in Veterans Receiving Maintenance Hemodialysis in the VA: An Interrupted Time-Series Analysis.
Patel S; Trujillo Rivera EA; Raman VK; Faselis C; Wang V; Fink JC; Roseman JM; Morgan CJ; Zhang S; Sheriff HM; Heimall MS; Wu WC; Zeng-Treitler Q; Ahmed A
Am J Nephrol; 2023; 54(11-12):508-515. PubMed ID: 37524062
[TBL] [Abstract][Full Text] [Related]
19. HIV Prevalence and HIV Screening History Among a Veterans Association Cohort of People with Opioid and Alcohol Use Disorders.
McCann NC; Davenport MJ; Mandavia AD; Stein MD; Livingston NA
J Gen Intern Med; 2024 Feb; 39(3):403-410. PubMed ID: 37848765
[TBL] [Abstract][Full Text] [Related]
20. Disparities in routine healthcare utilization disruptions during COVID-19 pandemic among veterans with type 2 diabetes.
Adhikari S; Titus AR; Baum A; Lopez P; Kanchi R; Orstad SL; Elbel B; Lee DC; Thorpe LE; Schwartz MD
BMC Health Serv Res; 2023 Jan; 23(1):41. PubMed ID: 36647113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
